Altimmune, Inc.
NASDAQ:ALTBiotechnology
+$0.08 today
- Market cap
- $270.48M
- Beta
- 0.23
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$0.73
Volume 4.69M
Average 3.81M
ALT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Altimmune, Inc.NASDAQ: ALT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $23K fell 20.7% year over year, ahead of the -33.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 11.5% from the prior quarter. Over 3 fiscal years it compounded at -39.0% a year.
Context
- Depreciation & amortization amounted to 273.2% of revenue in FY2025, down 916.8 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -20.7% holds above the trailing-twelve-month pace of -33.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 112K USD
- Year-over-year change
- -52.9%
- 4-year CAGR
- -32.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 112K | -52.9% |
| FY2024 | 2024-12-31 | 238K | -50.1% |
| FY2023 | 2023-12-31 | 477K | -3.2% |
| FY2022 | 2022-12-31 | 493K | -10.5% |
| FY2021 | 2021-12-31 | 551K | — |
Depreciation & Amortization vs competitors
How ALT compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -33.8% is the 5th highest of 8, against a peer median of -10.0%.
- Depreciation & amortization amounts to 294.4% of revenue for ALT, versus a peer median of 7.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.62M USD | -10.0% | +19.9% | 17.7% | |
| LTM Mar 2026 | $4.93M USD | +55.9% | +19.6% | 7.1% | |
| FY2025 | €2.8M EUR | -46.2% | +47.6% | 62.4% | |
| LTM Jun 2026 | $1.92M USD | +74.2% | +141.5% | — | |
| LTM Mar 2026 | $1.02M USD | -43.2% | +26.8% | — | |
| LTM Mar 2026 | $122K USD | -6.2% | -36.3% | 0.2% | |
| LTM Mar 2026 | $106K USD | -33.8% | -39.0% | 294.4% | |
| LTM Mar 2026 | $44K USD | -96.8% | -36.6% | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding ALT) | — | -10.0% | +19.9% | 7.1% | |
Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.41M | (68K) | 426K | 20K | 41K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 4.41M | (68K) | 426K | 20K | 41K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 74.54M | 70.54M | 65.8M | 82.23M | 66.43M |
| Selling, General & Admin | 15.41M | 17.13M | 18.14M | 20.97M | 28.1M |
| Operating Expenses | 101.32M | 87.67M | 96.36M | 103.19M | 94.53M |
| Depreciation & Amortization | 551K | 493K | 477K | 238K | 112K |
| EBITDA | (96.53M) | (84.41M) | (87.94M) | (94.81M) | (87.03M) |
| EBITDA Margin | -2189.0% | 124130.9% | -20642.0% | -474060.0% | -212258.5% |
| Operating Income | (96.91M) | (87.74M) | (95.93M) | (103.17M) | (94.49M) |
| Operating Margin | -2197.6% | 129029.4% | -22518.5% | -515860.0% | -230461.0% |
| Interest Income | 203K | 2.87M | 7.35M | 8.07M | 7.54M |
| Interest Expense | 5K | 8K | 35K | 9K | 1.64M |
| Other Income / Expenses | (176K) | 2.83M | 7.48M | 8.11M | 5.72M |
| Income Before Tax | (97.09M) | (84.91M) | (88.45M) | (95.06M) | (88.77M) |
| Pre-Tax Margin | -2201.6% | 124867.6% | -20762.2% | -475295.0% | -216522.0% |
| Income Tax Expense | 0 | (197K) | 0 | 0 | (681K) |
| Net Income | (97.09M) | (84.71M) | (88.45M) | (95.06M) | (88.09M) |
| Net Margin | -2201.6% | 124577.9% | -20762.2% | -475295.0% | -214861.0% |
| EPS (Basic) | (2.35) | (1.81) | (1.66) | (1.34) | (1.00) |
| EPS (Diluted) | (2.35) | (1.81) | (1.66) | (1.34) | (1.00) |
| Weighted Avg Shares | 41.28M | 46.93M | 53.25M | 71M | 88.1M |
| Weighted Avg Shares (Diluted) | 41.28M | 46.93M | 53.25M | 71M | 88.1M |
Altimmune, Inc.
NASDAQ:ALT
Intrinsic Alpha fair value
Locked
Current Price
$1.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.